Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

16.7%

1 terminated/withdrawn out of 6 trials

Success Rate

75.0%

-11.5% vs industry average

Late-Stage Pipeline

33%

2 trials in Phase 3/4

Results Transparency

100%

3 of 3 completed trials have results

Key Signals

1 recruiting3 with results

Enrollment Performance

Analytics

Phase 4

2(40.0%)

N/A

2(40.0%)

Early Phase 1

1(20.0%)

5Total

Phase 4(2)

N/A(2)

Early Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT02897908Recruiting

Non-invasive Liver Screening Using FibroScan Device for Liver Disease Patients for the Steatosis/Fibrosis Database

Role: collaborator

NCT01420328Not ApplicableCompleted

To Study the Effect of Vytorin on Intracellular Lipid and Inflammation in Obese Subjects

Role: collaborator

NCT02372630Phase 4Completed

The Effect of LINAGLIPTIN on Inflammation, Oxidative Stress and Insulin Resistance in Obese Type 2 Diabetes Subjects

Role: collaborator

NCT01158417Not ApplicableTerminated

Resveratrol in Type2 Diabetes and Obesity

Role: collaborator

NCT02433678Phase 4Completed

An Investigation Into The Anti-hypertensive And Potential Anti-inflammatory Actions Of Dapagliflozin

Role: collaborator

NCT01526824Early Phase 1Unknown

Lovaza's Effect on Clopidogrel in a Neuro Population

Role: collaborator

All 6 trials loaded